Cultivation Capital, a St. Louis, Missouri-based venture capital firm, has launched its second fund dedicated to life sciences startups.
Cultivation Capital Life Sciences Fund II, LLC, has a final target of $40m. According to a regulatory form filed with the SEC, five investors already participated in the offering committing $2.25m.
Led by Managing Partner William Schmidt, and General Partners Dean VandeKamp, Rick Ryan, David Smoller, Rick Holton Jr., Chris Danforth, and Bobby Sandage,
Cultivation Capital Life Sciences Fund II invests in early-stage life sciences companies, primarily in the therapeutics, diagnostics, research tools and reagents, medical devices, and healthcare information technology verticals.
The fund provides post-seed/pre-Series A stage companies with the capital they need to scale their businesses. Initial investment ranges from $250,000 – $1,000,000, with opportunities for follow-on investment.
The life sciences portfolio of the firm includes Benson Hill Biosystems, BlueStrata EHR, Cardialen, Euclises Pharmaceuticals, Galera Therapeutics, Immunophotonics, Mobius Therapeutics, Molecular Sensing, Pulse Therapeutics, Vasculox, and Veniti.